Literature DB >> 21969054

RAB8 enhances TMEM205-mediated cisplatin resistance.

Ding-Wu Shen1, Michael M Gottesman.   

Abstract

PURPOSE: To determine whether the small endosomal recycling GTPase, RAB8, plays a role in TMEM205-associated resistance to the chemotherapeutic drug cisplatin.
METHODS: Antibodies were used as markers for both genes; confocal microscopy was used to visualize their localization in cisplatin-resistant cells. Both single and dual-transfections were performed.
RESULTS: Expression of RAB8 was markedly elevated in human cisplatin-resistant cells. We found that TMEM205 was co-localized with RAB8. Dual transfectants with over-expression of both TMEM205 and RAB8 were found to be up to 4-fold more resistant to cisplatin, while cells transfected with RAB8 alone were ~2-fold more resistant.
CONCLUSIONS: The development of cisplatin resistance appears to be a consequence of pleotropic epigenetic alterations. We unravel the role of one gene, the GTPase RAB8, in this process. Because its highest expression was at an early step of cisplatin resistance, it may be involved in early development of resistance. Increased expression of TMEM205 and RAB8 in double-transfected cells and their increased resistance to cisplatin indicate an additive effect of these two genes, mediating cisplatin resistance. These two proteins are potential biomarkers or targets for gene or chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969054      PMCID: PMC3288766          DOI: 10.1007/s11095-011-0562-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

Review 1.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

Authors:  Matthew D Hall; Mitsunori Okabe; Ding-Wu Shen; Xing-Jie Liang; Michael M Gottesman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

2.  Role of transporter genes in cisplatin resistance.

Authors:  V Badireenath Konkimalla; Bernd Kaina; Thomas Efferth
Journal:  In Vivo       Date:  2008 May-Jun       Impact factor: 2.155

3.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.

Authors:  Robert L Strausberg; Elise A Feingold; Lynette H Grouse; Jeffery G Derge; Richard D Klausner; Francis S Collins; Lukas Wagner; Carolyn M Shenmen; Gregory D Schuler; Stephen F Altschul; Barry Zeeberg; Kenneth H Buetow; Carl F Schaefer; Narayan K Bhat; Ralph F Hopkins; Heather Jordan; Troy Moore; Steve I Max; Jun Wang; Florence Hsieh; Luda Diatchenko; Kate Marusina; Andrew A Farmer; Gerald M Rubin; Ling Hong; Mark Stapleton; M Bento Soares; Maria F Bonaldo; Tom L Casavant; Todd E Scheetz; Michael J Brownstein; Ted B Usdin; Shiraki Toshiyuki; Piero Carninci; Christa Prange; Sam S Raha; Naomi A Loquellano; Garrick J Peters; Rick D Abramson; Sara J Mullahy; Stephanie A Bosak; Paul J McEwan; Kevin J McKernan; Joel A Malek; Preethi H Gunaratne; Stephen Richards; Kim C Worley; Sarah Hale; Angela M Garcia; Laura J Gay; Stephen W Hulyk; Debbie K Villalon; Donna M Muzny; Erica J Sodergren; Xiuhua Lu; Richard A Gibbs; Jessica Fahey; Erin Helton; Mark Ketteman; Anuradha Madan; Stephanie Rodrigues; Amy Sanchez; Michelle Whiting; Anup Madan; Alice C Young; Yuriy Shevchenko; Gerard G Bouffard; Robert W Blakesley; Jeffrey W Touchman; Eric D Green; Mark C Dickson; Alex C Rodriguez; Jane Grimwood; Jeremy Schmutz; Richard M Myers; Yaron S N Butterfield; Martin I Krzywinski; Ursula Skalska; Duane E Smailus; Angelique Schnerch; Jacqueline E Schein; Steven J M Jones; Marco A Marra
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

Review 4.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

5.  Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.

Authors:  Eiji Kashiwagi; Hiroto Izumi; Yoshihiro Yasuniwa; Ryoko Baba; Yoshiaki Doi; Akihiko Kidani; Tokuzo Arao; Kazuto Nishio; Seiji Naito; Kimitoshi Kohno
Journal:  Cancer Sci       Date:  2010-11-19       Impact factor: 6.716

6.  MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway.

Authors:  Jose J Bravo-Cordero; Raquel Marrero-Diaz; Diego Megías; Laura Genís; Aranzazu García-Grande; Maria A García; Alicia G Arroyo; María C Montoya
Journal:  EMBO J       Date:  2007-03-01       Impact factor: 11.598

7.  Oxaliplatin: a review in the era of molecularly targeted therapy.

Authors:  T Alcindor; N Beauger
Journal:  Curr Oncol       Date:  2011-01       Impact factor: 3.677

Review 8.  What makes tumors multidrug resistant?

Authors:  Piet Borst; Jos Jonkers; Sven Rottenberg
Journal:  Cell Cycle       Date:  2007-08-23       Impact factor: 4.534

Review 9.  Platinum resistance: the role of DNA repair pathways.

Authors:  Lainie P Martin; Thomas C Hamilton; Russell J Schilder
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

10.  Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.

Authors:  Katsuyuki Tozawa; Tadayuki Oshima; Takehiko Kobayashi; Noriyasu Yamamoto; Chizuko Hayashi; Takayuki Matsumoto; Hiroto Miwa
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480

View more
  15 in total

Review 1.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

2.  Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells.

Authors:  Lynn M Pouliot; Ding-Wu Shen; Toshihiro Suzuki; Matthew D Hall; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2012-11-05       Impact factor: 3.905

3.  A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(II)-drug resistance and extrusion.

Authors:  Marc J Gallenito; Tahir S Qasim; Jasmine N Tutol; Ved Prakash; Sheel C Dodani; Gabriele Meloni
Journal:  Metallomics       Date:  2020-10-21       Impact factor: 4.526

4.  RAB8A a new biomarker for endometrial cancer?

Authors:  Yachun Bie; Zhenyu Zhang
Journal:  World J Surg Oncol       Date:  2014-12-04       Impact factor: 2.754

Review 5.  Rab GTPases: Central Coordinators of Membrane Trafficking in Cancer.

Authors:  Hongyuan Jin; Yuanxin Tang; Liang Yang; Xueqiang Peng; Bowen Li; Qin Fan; Shibo Wei; Shuo Yang; Xinyu Li; Bo Wu; Mingyao Huang; Shilei Tang; Jingang Liu; Hangyu Li
Journal:  Front Cell Dev Biol       Date:  2021-06-01

Review 6.  Novel functions for Rab GTPases in multiple aspects of tumour progression.

Authors:  Chiara Recchi; Miguel C Seabra
Journal:  Biochem Soc Trans       Date:  2012-12-01       Impact factor: 5.407

7.  TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.

Authors:  Lionel Flamant; Edith Roegiers; Michael Pierre; Aurélie Hayez; Christiane Sterpin; Olivier De Backer; Thierry Arnould; Yves Poumay; Carine Michiels
Journal:  BMC Cancer       Date:  2012-09-06       Impact factor: 4.430

8.  The association of transporter genes polymorphisms and lung cancer chemotherapy response.

Authors:  Ying Wang; Ji-Ye Yin; Xiang-Ping Li; Juan Chen; Chen-Yue Qian; Yi Zheng; Yi-Lan Fu; Zi-Yu Chen; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

Review 9.  Systems biology of cisplatin resistance: past, present and future.

Authors:  L Galluzzi; I Vitale; J Michels; C Brenner; G Szabadkai; A Harel-Bellan; M Castedo; G Kroemer
Journal:  Cell Death Dis       Date:  2014-05-29       Impact factor: 8.469

10.  A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity.

Authors:  Zeneida Herrera-Pérez; Norbert Gretz; Harsh Dweep
Journal:  Curr Genomics       Date:  2016-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.